Pharmagen Stock Fundamentals
| PHRX Stock | USD 0.0001 0.00 0.00% |
Pharmagen fundamentals help investors to digest information that contributes to Pharmagen's financial success or failures. It also enables traders to predict the movement of Pharmagen Stock. The fundamental analysis module provides a way to measure Pharmagen's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pharmagen stock.
At this time, Pharmagen's Selling General Administrative is fairly stable compared to the past year. Total Revenue is likely to rise to about 5.8 M in 2024, despite the fact that Operating Income is likely to grow to (1.8 M). Pharmagen | Select Account or Indicator |
Pharmagen Company Return On Asset Analysis
Pharmagen's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Pharmagen Return On Asset | -0.59 |
Most of Pharmagen's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharmagen is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pharmagen Return On Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Pharmagen is extremely important. It helps to project a fair market value of Pharmagen Stock properly, considering its historical fundamentals such as Return On Asset. Since Pharmagen's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pharmagen's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pharmagen's interrelated accounts and indicators.
Click cells to compare fundamentals
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Pharmagen Total Assets
Total Assets |
|
Based on the latest financial disclosure, Pharmagen has a Return On Asset of -0.5891. This is 93.27% lower than that of the Health Care Providers & Services sector and 120.38% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Pharmagen Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Pharmagen's current stock value. Our valuation model uses many indicators to compare Pharmagen value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pharmagen competition to find correlations between indicators driving Pharmagen's intrinsic value. More Info.Pharmagen is rated below average in return on asset category among its peers. It also is rated below average in profit margin category among its peers . At this time, Pharmagen's Net Loss is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Pharmagen's earnings, one of the primary drivers of an investment's value.Pharmagen Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharmagen's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pharmagen could also be used in its relative valuation, which is a method of valuing Pharmagen by comparing valuation metrics of similar companies.Pharmagen is currently under evaluation in return on asset category among its peers.
Pharmagen Fundamentals
| Return On Asset | -0.59 | ||||
| Profit Margin | (1.33) % | ||||
| Operating Margin | (0.31) % | ||||
| Current Valuation | 5.93 M | ||||
| Shares Outstanding | 517.08 M | ||||
| Price To Earning | (0.06) X | ||||
| Price To Sales | 0.08 X | ||||
| Revenue | 4.81 M | ||||
| Gross Profit | 3.05 M | ||||
| EBITDA | (2.13 M) | ||||
| Net Income | (6 M) | ||||
| Cash And Equivalents | 264.67 K | ||||
| Total Debt | 2.16 M | ||||
| Current Ratio | 0.10 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (692.07 K) | ||||
| Target Price | 0.13 | ||||
| Number Of Employees | 24 | ||||
| Beta | -0.065 | ||||
| Market Capitalization | 361.95 K | ||||
| Total Asset | 1.28 M | ||||
| Working Capital | (7.46 M) | ||||
| Current Asset | 837 K | ||||
| Current Liabilities | 8.29 M | ||||
| Net Asset | 1.28 M |
About Pharmagen Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharmagen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharmagen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharmagen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 5.5 M | 5.8 M | |
| Cost Of Revenue | 2 M | 1.4 M | |
| Stock Based Compensation To Revenue | 0.02 | 0.02 | |
| Sales General And Administrative To Revenue | 0.60 | 0.53 | |
| Capex To Revenue | 0.01 | 0.01 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (0.40) | (0.42) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pharmagen Stock Analysis
When running Pharmagen's price analysis, check to measure Pharmagen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharmagen is operating at the current time. Most of Pharmagen's value examination focuses on studying past and present price action to predict the probability of Pharmagen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharmagen's price. Additionally, you may evaluate how the addition of Pharmagen to your portfolios can decrease your overall portfolio volatility.